Gilead Sciences, Inc. (NASDAQ: GILD) today announced that 10 abstracts describing the company's investigational agents for several hematological malignancies have been selected for presentation at the Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10 in New Orleans. The abstracts describe clinical and pre-clinical data from studies of idelalisib, which is currently under review by the U.S. Food and Drug Administration for treatment of refractory indolent non-Hodgkin’s lymphoma (iNHL), as well as for GS-9973, GS-9820 and momelotinib (formerly CYT387 / GS-0387). Detailed results from these studies will be presented at the conference.
“We are encouraged by the data across our hematologic oncology pipeline that will be presented at the ASH annual meeting,” said Roy Baynes, MD, PhD, Senior Vice President of Oncology and Inflammation Therapeutics at Gilead Sciences. “We are moving forward quickly to fully explore the potential clinical benefit of idelalisib and other investigational agents against a range of hematological cancers.”
Presentations on idelalisib, Gilead's investigational, targeted, oral inhibitor of PI3K delta include:
Clinical data on other oral investigational compounds in development for the treatment of hematologic malignancies also will be presented, including:
Abstracts for Gilead's presentations can be accessed at http://www.hematology.org/Meetings/Annual-Meeting/. Further information about the clinical studies described above can be found at www.clinicaltrials.gov.
Idelalisib, momelotinib, GS-9973 and GS-9820, each as single-agents and in combination with other agents, are investigational products, and their safety and efficacy have not been established.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from clinical trials involving idelalisib, momelotinib, GS-9973 and GS-9820, as single agents or in combination with other agents. In addition, Gilead may not initiate its Phase 3 clinical program for momelotinib in the currently anticipated timelines. Gilead faces risks related to its ability to enroll patients in future clinical studies for these agents and may need to modify or delay these studies. Further, Gilead may make a strategic decision to discontinue development of idelalisib, momelotinib, GS-9973 and GS-9820 if, for example, Gilead believes commercialization will be difficult relative to other opportunities in its pipeline. As a result, idelalisib, momelotinib, GS-9973 and GS-9820 may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
|Agios Pharmaceuticals to Present Preclinical Research at the 2013 American Society of Hematology Annual Meeting (2013/11/7)|
|New Data Highlighting Foundation Medicine’s Second Clinical Product to be Presented at American Society of Hematology Annual Meeting (2013/11/8)|
|Acceleron Announces New Interim Phase 2 Sotatercept Clinical Data in Beta-Thalassemia to be Presented at 2013 American Society of Hematology Annual Meeting (2013/12/2)|
|Mirati Therapeutics to Present Data on Phase 1/2 Trial of Mocetinostat at the 55th American Society of Hematology Annual Meeting ()|
|Data from Bio-Path Holdings Phase I Clinical Trial in Hematological Cancers to be Presented at American Society of Hematology Annual Meeting ()|
|Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting (2013/11/7)|
|Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting (2013/11/20)|
|CTI Announces Data Presentations at the 55th American Society of Hematology Annual Meeting (2013/11/7)|
|Emergent BioSolutions Announces Acceptance of Otlertuzumab Abstracts for Presentation at 2013 American Society of Hematology Annual Meeting ()|
|Acceleron and Celgene Report New Interim Clinical Data from Phase 2 Trial of Sotatercept in Beta-Thalassemia at 2013 American Society of Hematology Annual Meeting ()|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.